Lavifice 250 Tablet contains Levetiracetam 250 mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Lavifice 250 is typically prescribed as adjunctive therapy in patients who do not achieve adequate seizure control with monotherapy. The tablet should be administered orally, with dosage individualized based on patient age, renal function, and clinical response. Common adverse effects may include somnolence, dizziness, headache, and fatigue; serious side effects are rare but can include behavioral changes, hypersensitivity reactions, and coordination difficulties. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Lavifice 250 does not induce or inhibit hepatic enzymes significantly, minimizing drug-drug interactions. It is essential to adhere to prescribed dosing and not discontinue therapy abruptly to prevent seizure exacerbation. Regular monitoring and follow-up with a healthcare provider are recommended to optimize treatment outcomes and manage potential side effects. This medication should be used under strict medical supervision.